Close Menu

Tecan

The single-molecule sequencing technology company has named the 11 firms that are the initial members of its new partner program, which is aimed at providing customers with complete solutions.

Enigma struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its miniaturized PCR instrument for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.

Tecan will manufacture Enigma's new point-of-care molecular diagnostic instrument under a five-year deal.

New Products: Dec 8, 2009

Premium

Fluidigm 48.48 Access Array, DNAStar Lasergene v8.1, NuGen Ovation RNA-seq

Product Watch: Dec 3, 2009

Premium

Thermo Fisher's Verbatim High Fidelity DNA Polymerase; WaferGen's SmartChip PCR services; NuGen Ovation for RNA-Seq; ZyGem's forensicGEM saliva DNA extraction kit

IP Roundup, Nov 10, 2019

Premium

University of Illinois, SRU Biosystems, Asahi Kasei, Fred Hutchinson Cancer Research Center, Institute for Systems Biology, Affymetrix, Stanford University, Tecan, CapitalBio

New Product Watch: Nov 3, 2009

Premium

Akonni Biosystems, NuGen Technologies

As part of a planned foray into next-generation sequencing technologies, the firm will move into larger housing in San Carlos, and open a new Seattle facility.

By year's end, NuGen plans to launch an RNA-seq sample-preparation kit that allows users to start with less material, and plans to add "many more products for NGS in the near future."

Paired Ends: Oct 13, 2009

Premium

Christopher Raymond, Dennis Ausiello, David Baltimore, Eli Broad, Drew Gilpin Faust, Jeffrey Flier, Susan Hockfield, Seth Klarman, Eric Lander, William Lee, Arthur Levinson, Phillip Sharp, Patty Stonesifer, Ratan Tata, Diana Chapman Walsh

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.